IgA dominates the early neutralizing antibody response to SARS-CoV-2

Archive ouverte

Sterlin, Delphine | Mathian, Alexis | Miyara, Makoto | Mohr, Audrey | Anna, François | Claër, Laetitia | Quentric, Paul | Fadlallah, Jehane | Devilliers, Hervé | Ghillani, Pascale | Gunn, Cary | Hockett, Rick | Mudumba, Sasi | Guihot, Amélie | Luyt, Charles-Edouard | Mayaux, Julien | Beurton, Alexandra | Fourati, Salma | Bruel, Timothée | Schwartz, Olivier | Lacorte, Jean-Marc | Yssel, Hans | Parizot, Christophe | Dorgham, Karim | Charneau, Pierre | Amoura, Zahir | Gorochov, Guy

Edité par CCSD ; American Association for the Advancement of Science (AAAS) -

International audience. Humoral immune responses are typically characterized by primary IgM antibody responses followed by secondary antibody responses associated with immune memory and comprised of of IgG, IgA and IgE. Here we measured acute humoral responses to SARS-CoV-2, including the frequency of antibody-secreting cells and the presence of SARS-CoV-2-specific neutralizing antibodies in the serum, saliva and broncho-alveolar fluid of 159 patients with COVID-19. Early SARS-CoV-2-specific humoral responses were dominated by IgA antibodies. Peripheral expansion of IgA plasmablasts with mucosal-homing potential was detected shortly after the onset of symptoms and peaked during the third week of the disease. The virus-specific antibody responses included IgG, IgM and IgA, but IgA contributed to virus neutralization to a greater extent compared with IgG. Specific IgA serum concentrations decreased notably one month after the onset of symptoms, but neutralizing IgA remained detectable in saliva for a longer time (days 49 to 73 post symptoms). These results represent a critical observation given the emerging information as to the types of antibodies associated with optimal protection against re-infection, and whether vaccine regimens should consider targeting a potent but potentially short-lived IgA response.

Suggestions

Du même auteur

Pre-COVID-19 Immunity to Common Cold Human Coronaviruses Induces a Recall-Type IgG Response to SARS-CoV-2 Antigens Without Cross-Neutralisation

Archive ouverte | Miyara, Makoto | CCSD

International audience. The capacity of pre-existing immunity to human common coronaviruses (HCoV) to cross-protect against de novo COVID-19is yet unknown. In this work, we studied the sera of 175 COVID-19 patients,...

Identification of natural killer markers associated with fatal outcome in COVID-19 patients

Archive ouverte | Tarantino, Nadine | CCSD

International audience. Introduction: Increasing evidence has shown that coronavirus disease 19 (COVID-19) severity is driven by a dysregulated immunological response. Previous studies have demonstrated that natural...

Distinct cytokine profiles associated with COVID-19 severity and mortality

Archive ouverte | Dorgham, Karim | CCSD

International audience. Background: Markedly elevated levels of proinflammatory cytokines and defective type-I interferon responses were reported in patients with coronavirus disease 2019 (COVID-19).Objective: We so...

Chargement des enrichissements...